Home Cart Sign in  
Chemical Structure| 1627929-55-8 Chemical Structure| 1627929-55-8

Structure of PLX51107
CAS No.: 1627929-55-8

Chemical Structure| 1627929-55-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

PLX51107 is a potent and selective BRD4 inhibitor or BET inhibitor with novel in vitro and in vivo pharmacologic properties that emulates or exceeds the efficacy of BCR signaling agents in preclinical models of CLL.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of PLX51107

CAS No. :1627929-55-8
Formula : C26H22N4O3
M.W : 438.48
SMILES Code : O=C(O)C1=CC=C(C2=CN([C@H](C3=NC=CC=C3)C)C4=CC(C5=C(C)ON=C5C)=CN=C42)C=C1
MDL No. :MFCD31657388
InChI Key :AMSUHYUVOVCWTP-INIZCTEOSA-N
Pubchem ID :90448953

Safety of PLX51107

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of PLX51107

epigenetics

Isoform Comparison

Biological Activity

Target
  • BET

    BRD3 BD1, Kd:2.1 nM

    BRD4 BD2, Kd:1.7 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
OCI-AML3 1 µM 96 hours CGM097 showed synergy with AZD6244 in OCI-AML3 cells PMC10913666
OCI-AML3 cells 250 nM 3 hours Evaluate the inhibitory effect of PLX51107 on MYC expression PMC8017818
MOLM-14 cells 79 nM Evaluate the inhibitory effect of PLX51107 on FLT3-ITD mutated AML cells PMC8017818
Primary CLL cells 1μM 4 hours To assess the effect of PLX51107 on BRD4 binding, results showed significant reduction in BRD4 load at enhancer regions PMC5882533
Omm1.3 cells 0.5 μM 48 hours Validate the synergistic effect of PTL with PLX51107, inhibiting NF-κB signaling and inducing apoptosis. PMC6643281
92.1 cells 0.04-5 μM 72 hours Evaluate the combinatorial therapeutic effects of PLX51107 with a compound library, identifying NF-κB inhibitors PTL and PDTC as synergistic with PLX51107. PMC6643281
MOLM-13 1 µM 96 hours To evaluate the effect of PLX51107 on AML cell viability, results showed that PLX51107 reduced AML cell viability PMC10913666
MV4-11 1 µM 96 hours To evaluate the effect of PLX51107 on AML cell viability, results showed that PLX51107 reduced AML cell viability PMC10913666
M238 cells 1, 2 and 4 μM 24 hours to 3 weeks PLX51107 combined with BRAFi/MEKi significantly inhibited the growth of M238 cells and reduced S-phase entry. PMC7078299
1205Lu cells 1, 2 and 4 μM 24 hours to 3 weeks PLX51107 combined with BRAFi/MEKi significantly inhibited the growth of 1205Lu cells and reduced S-phase entry. PMC7078299
A375 cells 1, 2 and 4 μM 24 hours to 3 weeks PLX51107 combined with BRAFi/MEKi significantly inhibited the growth of A375 cells and reduced S-phase entry. PMC7078299
MV4-11 cells 62 nM Evaluate the inhibitory effect of PLX51107 on FLT3-ITD mutated AML cells PMC8017818
DLBCL cell lines (SUDHL6, OCI-LY1, OCI-LY8, DOHH2) 1000 nM 48 hours In BCL-2-high DLBCL cell lines, PLX51107 and PLX2853 showed limited efficacy alone but exhibited synergistic effects when combined with the BH3 mimetic ABT199, significantly enhancing apoptosis. PMC7391160
Em-myc lymphoma cell lines 1000 nM 48 hours PLX51107 and PLX2853 induced apoptosis by upregulating BIM protein and suppressing the miR-17~92 cluster, resulting in cytotoxic responses in BCL-2-low MYC-driven lymphomas. PMC7391160
Rheumatoid arthritis patient CD14+ monocytes 50, 250 nM 48 hours To evaluate the effect of PLX51107 on FcγR expression in monocytes from rheumatoid arthritis patients. Results showed that PLX51107 significantly downregulated FcγRIIa, FcγRIIb, FcγRIIIa, and γ chain mRNA expression, while upregulating FcγRIa expression. PMC10143512
Healthy donor CD14+ monocytes 50, 100, 200, 250 nM 24 hours To evaluate the effect of PLX51107 on the transcriptional expression of FcγRIIa, FcγRIIb, FcγRIIIa, and FcεRIγ. Results showed that PLX51107 significantly downregulated FcγRIIa, FcγRIIb, and FcγRIIIa mRNA expression, while upregulating FcγRIa expression. PMC10143512
HBLAK 0.6 µM 72 hours PLX51107 inhibited cell growth, caused DNA damage, and blocked DNA repair response in UC cells PMC8002916
UM-UC-3 8.8 µM 72 hours PLX51107 inhibited cell growth, caused DNA damage, and blocked DNA repair response in UC cells PMC8002916
VM-CUB1 2 µM 72 hours PLX51107 inhibited cell growth, caused DNA damage, and blocked DNA repair response in UC cells PMC8002916
THJ-16T cells 500 nM 5 days Evaluate the effect of PLX on cell proliferation, results showed that PLX inhibited the proliferation of THJ-16T cells, reducing cell numbers by 88.4%. PMC6938575
THJ-11T cells 500 nM 5 days Evaluate the effect of PLX on cell proliferation, results showed that PLX inhibited the proliferation of THJ-11T cells, reducing cell numbers by 88.9%. PMC6938575

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Eμ-TCL1 transgenic mouse model Oral gavage 20 mg/kg Once daily for eight days To assess the effect of PLX51107 on leukemia burden, results showed significant reduction in leukemic cells in peripheral blood and spleen PMC5882533
Athymic nu/nu mice R-Omm1.3 xenograft model Oral and intraperitoneal injection PLX51107 20 mg/kg orally Three times a week for 5 weeks Evaluate the effect of PLX51107 combined with PTL on BETi-resistant tumors, showing significant inhibition of tumor growth. PMC6643281
NSG mice MOLM-13-luciferase xenograft model Oral gavage 20 mg/kg Daily administration until the end of the experiment To evaluate the anti-leukemic effect of PLX51107 in vivo, results showed that PLX51107 significantly prolonged the survival of mice PMC10913666
Nude mice 1205Lu and A375 xenograft models Oral 90 ppm Intermittent dosing (2 days on/5 days off) Intermittent PLX51107 combined with BRAFi/MEKi treatment significantly delayed tumor recurrence and improved animal survival. PMC7078299
SCID mice MV4-11 xenograft model Oral 10, 20, 40 mg/kg Once daily for 14 days Evaluate the anti-tumor effect of PLX51107 as a single agent in FLT3-ITD AML xenograft model PMC8017818
Mice Em-myc lymphoma model Oral gavage 10 mg/kg Once daily, 5 consecutive days/week PLX51107 and PLX2853 showed significant therapeutic effects in wild-type Em-myc lymphoma models but limited efficacy in BCL-2-high models. Combination with the BH3 mimetic ABT199 significantly enhanced tumor control. PMC7391160
DBA mice Collagen-induced arthritis model Oral gavage 10 mg/kg Three times per week for 5 weeks To evaluate the effect of PLX51107 on FcγR expression and arthritis symptoms in vivo. Results showed that PLX51107 significantly reduced footpad swelling and downregulated FcγR expression in monocytes and macrophages in the spleen. PMC10143512
Mice BrafV600E, Ptennull, Cdkn2dnul1 YUMM1.7 tumor model Oral 557-1500 ng/ml 12 days PLX51107 significantly delayed melanoma growth, reduced the frequency of tumor-infiltrating Tregs, increased the CD8/Tregs ratio, and decreased PD1 expression on CD8+ T cells. Combined with anti-PD-L1, it significantly inhibited tumor growth. PMC6591077
Nude mice Xenograft model Oral 24 mg/kg/day Once daily for 24 days or 48 days Evaluate the inhibitory effect of PLX on tumor growth, results showed that PLX significantly inhibited the growth of xenograft tumors. PMC6938575

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02683395 Solid Tumors|Acute Myeloid Leu... More >>kemia|Myelodysplastic Syndrome|Non-Hodgkin's Lymphoma Less << PHASE1 TERMINATED 2025-09-18 Columbia University Medical Ce... More >>nter, New York, New York, 10032, United States|The Ohio State University Stephanie Spielman Comprehensive Breast Center, Columbus, Ohio, 43212, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, United States|MUSC/ Hollings Cancer Center, Charleston, South Carolina, 29425, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, 78229, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.28mL

0.46mL

0.23mL

11.40mL

2.28mL

1.14mL

22.81mL

4.56mL

2.28mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories